Central Drugs Standard Control Organization

Directorate General of Health Services
Ministry of Health & Family Welfare
Government of India

Circulars

S.no Title Release Date Download Pdf Pdf Size
1 Circular regarding submission of Immovable property Return for the year of 2022 2022-Dec-21 630 KB
2 Information Document on Prevention of Sexual Harassment of Women at Workplace 2022-Nov-04 478 KB
3 Information Document on Suspension 2022-Nov-04 430 KB
4 Circular regarding information document on pay fixation issued by Department of personnel and Training 2022-Sep-13 684 KB
5 Circular regarding Information document on increment issued by Department of personnel and Training 2022-Sep-12 624 KB
6 Har Ghar Tiranga Campaign 2022-Jul-13 812 KB
7 Office Memorandum regarding Sexual Harassment of Women at work Place constitution of a complaints committee 2022-Jun-17 856 KB
8 Modification of Instructions regarding Booking of Air Tickets on Government account 2022-Jun-16 1453 KB
9 Circular regarding filling up for the post of Junior Scientific Assistant CDTL Mumbai 2022-Jan-12 5011 KB
10 Circular regarding attendance dated 7 Jan 2022 2022-Jan-07 116 KB
11 Circulars dated 27 Oct 2021 regarding 2021-Oct-27 901 KB
12 Prior approval for Global Tender Enquiry under rule 161(Vi) of General Financial Rules (GFRs) 2021-Oct-14 1338 KB
13 Office Order regarding the Leaves(s) in respect of the officers of CDSCO 2021-Oct-12 432 KB
14 Special condition under which the permission for import of drug with residual shelf life less than 60% is allowed 2021-Sep-13 316 KB
15 Office order regarding leaves granted to Officers of CDSCO 2021-Aug-19 930 KB
16 Circular regarding Azadi Ka Amrit Mahotsav 2021-Aug-12 2039 KB
17 Circular regarding attending office during Parliament Session 2021-Aug-03 1880 KB
18 Data for Income Tax Calculation for the Financial Year 2021-22 2021-Aug-02 3990 KB
19 Clarification if change in a) Polymorphs/crystalline/amorphous/solvates/hydrate etc (b) salt and (c) Derivative/analogue/ester etc of already approved active substance to be considered as new drug if main active moiety (Active Pharmaceutical Ingredient-API) is same? 2021-Jul-23 131 KB
20 Circular regarding attending office regularly dated 07.07.2021 2021-Jul-07 602 KB
21 Consolidated Instructions for Global Tender Enquiry (GTE) under Rule 161(iv) of General Financial Rules (GFRs), 2017 2021-Jul-07 3372 KB
22 Reconstituting of Internal Complaint Committee on sexual Harassment cases regarding 25 june 2021 2021-Jun-25 920 KB
23 Special Condition under which the permission for import of drug with residual shelf life less than 60% is allowed 2021-Apr-13 373 KB
24 RT-PCR Test for COVID-19 of the staff of CDSCO at FDA bhawan 2021-Apr-07 908 KB
25 Declaration of Holiday on 14th April 2021 Dr. B R Ambedkar 2021-Mar-31 334 KB
26 Office Meorandum regarding for pusuing higher qualification 2021-Mar-26 735 KB
27 Office Memorandum regarding submission of immovable property retrun for the year 2020 2021-Jan-05 1811 KB
28 Circulars dated 18 December 2020 2020-Dec-18 520 KB
29 Clarification regarding admissibility of Transport allowance druing Nation-Wide Lockdown due to COVID-19 pandemic 2020-Dec-08 328 KB
30 Clarification regarding reference standards 2020-Dec-04 260 KB
31 Submmission on Leave application in i-connect leave management System 2020-Oct-07 493 KB
32 circular regarding Special Condition under which the permission for import of drug with residual shelf life less than 60 % is allowed 2020-Jul-10 212 KB
33 Circular regarding Extension of validity of BA/BE Study Centres regarding 2020-Apr-30 344 KB
34 Circular regarding pocdure for lot release of Human vaccine in view of prevailing COVID-19 pandemic 2020-Apr-03 454 KB
35 Circular regarding exemption of biometric machine attendance till 31.03.2020 2020-Mar-06 857 KB
36 Circular regarding disposal of the application of WC for active substances exported to the Eu for medicinal products for Human use in accordance with Acrticle 42(2) 2020-Mar-04 664 KB
37 Circular regarding Disposal of the application of WHO-GMP 2020-Mar-03 617 KB
38 Circular Submission of certifice copy of APAR for consideration for Promotion confirmation grant of MACP etc to CDSCO HQ 2020-Feb-17 116 KB
39 Circular regarding Rational use of Antibiotics for limiting Antimicrobial resistance 2019-Dec-23 766 KB
40 Information/Guidance regarding uploading of manufacturing site and formulations data on SUGAM Portal 2019-Nov-29 384KB
41 Circular regarding clarification on stability data requirement in case of Clinical Trial and Bioavailability-Bioequivalance study 2019-Oct-18 668 KB
42 Clarification on stability data requirement in case of CT and BABE study 2019-Oct-18 516 KB
43 Circular regarding procedure for booking of air-tickets on LTC 2019-Sep-30 235 KB
44 Circulard dated 11 September 2019 2019-Sep-11 53 KB
45 Circular regarding WC dated 9.9.2019 2019-Sep-09 755 KB
46 Clarification on manufacturing of new drug by a manufacturer in their own multiple manufactring site 2019-Aug-30 89 KB
47 NOC for manufacture of Unapproved Banned New Drugs solely for Export purpose 2019-Aug-05 425 KB
48 Disposal of unserviceable/obsolete item of CDSCO 2018-Dec-21 322 KB
49 Pending Annual Performance Appraisal Report APARs of Drugs Inspectors in CDSCO regarding 2018-Sep-27 735 KB
50 Creation of Veterinary cell at CDSCO(HQ), New Delhi 2018-Jul-03 388KB
51 Gazette Notification of Drug Inspector 2018-Apr-12 1,680lb
52 Additional information regarding Medical Devices Rules 2017 2018-Mar-16 1,230kb
53 NSQ Vi-Conjugate Typhoid Vaccine Batch No.TC010915 and Batch No. TC010417 of M/s Bio Med Pvt Ltd 2018-Mar-14 904kb
54 Request to advice the manufacturers to submit stability data of non patent and proprietary medicines for grant of permission 2017-Aug-18 274kb
55 Circular Establishment of facilities for ther activities of coating assembling of components, sterilization etc for devices 2017-Aug-09 562kb
56 Clarification regarding submission of application for post approval changes of human Vaccines 2017-Jul-18 302kb
57 Testing of Sample of Imported Vaccine 2017-Jun-05 1,420kb
58 Acknowledgement for Level-III post approval changes Annual Notifications of biological products (vaccines &r-DNA) 2017-May-26 485kb
59 Delegation of Power to Sign Licence and Rigistration 2017-Apr-13 2920kb
60 Merit List based on the written examination held on 09.04.2017 at NIB Noida for WHO Roational Fellowhip Selection 2017-Apr-10 3,500kb
61 Circular regarding Human Vaccine 2017-Feb-16 50kb
62 Circular regarding first time import/manufacture in the country of Active Pharmaceutical Ingredient API of a drug which has earlier been approved as New Drug in Finished Formulation for import and marketing and /or allowed for import under import registration and Licensing 2016-Dec-30 396kb
63 Circular regarding NOC for export of biological products (Vaccine and r-DNA products) under Form 29 license to manufacture drugs for purposes of examination, test or analysis 2016-Dec-13 237kb
64 Circular regarding extension of Shelf Life within or up to the period of 60 Months for export purpose 2016-Oct-27 309kb
65 Circular regarding requirement of approval of Review Committee on Genetic Manipulation under Department of Biotechnology for r-DNA 2016-Aug-30 487kb
66 Circular regarding Requirement of NOC from DCGI for addition of new Clinical trial site or investigator 2016-Aug-03 493kb
67 Circular regarding Requirement of 50 bedded site for clinical trial 2016-Aug-02 258kb
68 Circular regarding Restriction of conducting three clinical trials per investigator 2016-Aug-02 243kb
69 Manufacturing and Marketing of Unapproval Drug, VitaminK2-7 2016-Jan-01 39kb
70 Pre-Screening work 2015-Dec-30 244kb
71 Requirement of approval of Review Committee on Generic Manipulation (RCGM) under Department of Biotechnology for r-DNA derived drugs like Insulin, Monoclonal antibody, etc 2015-Nov-10 242kb
72 Circular to all State/UT's Drugs Controller 2015-Aug-06 46kb
73 Draft Senority List of Assistant Drugs Inspectors CDSCO 2015-Jul-13 752kb
74 Draft Senority List of Drugs Inspectors CDSCO 2015-Jul-01 3,240kb
75 Circular regarding Import of Cosmetics 2015-Jun-29 428kb
76 2015-Jun-17 337kb
77 Availability of H1N1 Vaccine 2015-Feb-17 48kb
78 Exemption of Veterinary products from the purview of DCG(I) Letter 2015-Jan-15 361KB
79 Circular regarding written confirmation certificate 2014-Oct-22 92kb
80 Circular regarding strict regulatory control over the manufacture,sale and distribution of Oxytocin 2014-Oct-22 897kb
81 Circular 2014-Sep-19 418kb
82 Minutes of Meeting 2014-Sep-08 22kb
83 Database of Fixed Dose Combinations (FDC's) Permitted for Manufacture for Sale in the Country 2014-Sep-05 574kb
84 Seventh Meeting of the Expert Committee on 29.08.2014 to examine the matters related to the approval of the safety and efficacy of Fixed Dose Combinations(FDC's) permitted for manufacture for sale in the country without due approval from office of DCG(I) 2014-Aug-29 262kb
85 Sixth Meeting of the Expert Committee on 27.08.2014 to examine the matters related to the approval of the safety and efficacy of Fixed Dose Combinations(FDC's) permitted for manufacture for sale in the country without due approval from office of DCG(I) 2014-Aug-27 274kb
86 Postponement of the Seventh Expert Committee Meeting from 29.08.2014 to 05.09.2014 to examine the matters related to the approval of the safety and efficacy of Fixed Dose Combinations(FDC's) permitted for manufacture for sale in the country without due approval from office of DCG(I) 2014-Aug-22 376kb
87 Specification and Criteria for Acceptance for test performed on blood glucose test strip and analyzer based glucose reagents 2014-Aug-07 359kb
88 Clarification on Form-29 for the Manufacture of Clinical Trial Material 2014-Jul-25 128kb
89 Use of antibiotcs for Treatment of food producing animals and in animal feed 2014-Jun-06 286kb
90 Approval of the safety and efficacy of FDC permitted for manufacture for sale in the country without due approval form office of DCG(I) 2014-Jun-05 167kb
91 Manufacture for sale in the country without due approval from office of DCG(I) 2014-May-26 174kb
92 Third Meeting of the Expert Committee on 04.06.2014 to examine the matters related to approval of the safety and efficacy of FDC permitted for manufacture for sale in the country without due approval from office of DCG(I) 2014-May-26 170kb
93 Fourth Meeting of the Expert Committee on 11.06.2014 to Examine the Matters Related to Approval of the safety and efficacy of FDC Permitted 2014-May-26 132kb
94 Second Meeting of the Expert Committee on 23.04.2014 to examine the matters related to the approval of the safety and efficacy of Fixed Dose Combinations(FDC's) permitted for manufacture for sale in the country without due approval from office of DCG(I) 2014-Apr-04 668kb
95 Approval of the safety and efficacy of FDCs 2014-Mar-28 311kb
96 Restriction on use of formulations of Tramadol, Tapentadol as well as FDCs containing Tramadol 2014-Feb-14 138kb
97 Cancellation of Permission of FDC of Olmesartan Medoxomil + Amlodipine + Hydrochlorothiazide tablets 2014-Feb-07 441kb
98 Circular Regarding Approval of Safety and Efficacy Marketed in the Country of FDC's Without Approval from DCG(I) 2014-Feb-03 322KB
99 Bringing details about Drug Import alert/restrictions imposed by regulatory authorities abroad 2014-Jan-28 504KB
100 Grant of Permission to Manufacture and Market FDC of Cefixime 200mg 2013-Nov-11 184KB
101 Grant of Permission to Manufacture and Market Certain FDC 2013-Nov-05 154kb
102 Grant of Permission to Manufacture and Market FDC of Ofloxacin 200mg 2013-Oct-17 147KB
103 Approval of the safety and efficacy of Fixed Dose Combinations(FDCs) permitted for manufacture for sale in country without due approval from office of DCG(I) 2013-Sep-02 866kb
104 Furnishing of information in respect of financial support, fees, honorarium, payments in kind etc to be paid to the investigator as per contract entered into by the sponsor with the investigator/ insititution in clinical trials 2013-Aug-30 310kb
105 Approval of the safety and efficacy of FDCs permitted for manufacture for sale in country without due approval form office of DCG(I) 2013-Aug-26 567kb
106 Circular dated 05.07.2013 regarding approval of the safety and efficacy of Fixed Dose Combinations (FDCs) permitted for manufacture for sale in the country without due approval from office of DCG(I) 2013-Jul-05 912kb
107 Circular regarding drug import alert/ restrictions imposed by regulatory authorities abroad 2013-Jun-26 343kb
108 Circular regarding re-labeling/re-printing of revised prices as per NPPA's 2013-Jun-26 499kb
109 Sub -rule 3A of Rule 97 of drugs and cosmetics rules 1945 regarding withdrawal period 2013-May-23 244kb
110 Letter regarding safety and efficacy of FDCs permitted by State Licensing Authority without prior approval from DCG(I) 2013-Mar-21 288kb
111 Letter Approval of the safety and efficacy of Fixed Dose Combinations Permitted for manufacture for sale in the country without due approval form office of DCG(I) 2013-Jan-15 681kb
112 Letter To establish the safety and efficacy of the FDC of Flupenthixol+Melitracen on Indian population. 2013-Jan-10 400kb
113 Letter Cancellation of permission/License in case an applicant/manufacturer fails to launch their product within a period of six month from obtaining the permission/license from CDSCO 2013-Jan-10 365kb
114 General Information on antibiotics and antibiotic resistance. 2012-Dec-10 84kb
115 Order issued to CDSCO Zonal Offices on Special drive for assuring the quality of medicines. 2012-Dec-05 384kb
116 Letter on Important safety label changes to cholesterol lowering stating drug. 2012-Nov-06 1,030kb
117 Order regarding “Box Warning” on label/package insert of formulations containing Nimesulide. 2012-Apr-14 280kb
118 Clarification regarding Limiting of Acetaminophen (Paracetamol) in prescription combination products. 2012-Apr-04 329kb
119 Circular regarding import of Cosmetic 2011-Nov-16 148kb
120 Cosmetic NOC 2011-Nov-16 144kb
121 Letter regarding Limiting of Acetaminophen (Paracetamol) in Prescription Combination Products 2011-Sep-23 116kb
122 Letter regarding Phasing out of oral Single Drug Formulations of Artemisinin. 2011-Apr-25 110kb
123 Letter regarding Information for submission to Department related Parliament Standing Committee on H&FW 2011-Feb-03 62kb
124 Letter regarding Prohibition of manufacture and sale of Rosiglitazone. 2010-Nov-16 156kb
125 Letter regarding Suspension of import/manufacture of rosiglitazone in the country. 2010-Oct-07 101kb